An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Perioperative durvalumab led to encouraging survival data in resectable NSCLC
An improvement was observed when immunotherapy was added to neoadjuvant chemotherapy, but further data are needed to confirm the survival benefit
Overall survival benefit achieved with amivantamab plus lazertinib in advanced EGFR-mutated NSCLC
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination
Novel ways presented to mitigate combination therapy toxicity in EGFR-mutant advanced NSCLC
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Subcutaneous pembrolizumab demonstrates noninferiority to intravenous administration
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Targeting KRAS G12C in NSCLC: balancing the benefit–risk profile of first-line combinations is still challenging
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Promising activity reported with second-line TKIs in oncogene-addicted advanced NSCLC
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
First-line combination of an antibody–drug conjugate plus immunotherapy shows promise in non-small cell lung cancer
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
Can AI and liquid biopsies take precision oncology to the next level?
According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor